

GLAXOSMITHKLINE PLC

Form 6-K

May 08, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending May 2015

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Result of AGM

GlaxoSmithKline plc ('GSK') announces that at its Annual General Meeting ('AGM') today, all resolutions were passed by shareholders.

GSK AGM Poll Results

The following table shows the votes cast for each resolution:

| Resolution | Total votes for* | % | Total votes against | % | Total votes cast | Votes withheld** |
|----------------------------------------------|------------------|-------|---------------------|------|------------------|------------------|
| 1 To receive the 2014 Annual Report | 3,614,278,186 | 99.04 | 35,131,332 | 0.96 | 3,649,409,518 | 14,897,298 |
| 2 Approval of the Annual Remuneration Report | 3,391,418,737 | 98.03 | 68,233,680 | 1.97 | 3,459,652,417 | 204,653,757 |
| 3 Election of Sir Philip Hampton | 3,591,444,657 | 99.08 | 33,187,186 | 0.92 | 3,624,631,843 | 39,673,560 |
| 4 Election of Urs Rohner | 3,646,088,522 | 99.85 | 5,657,074 | 0.15 | 3,651,745,596 | 12,559,808 |
| 5 Re-election of Sir Andrew Witty | 3,636,239,584 | 99.57 | 15,745,701 | 0.43 | 3,651,985,285 | 12,323,435 |
| 6 Re-election of Professor Sir Roy Anderson | 3,635,006,358 | 99.54 | 16,926,524 | 0.46 | 3,651,932,882 | 12,372,971 |
| 7 Re-election of Dr Stephanie Burns | 3,640,064,153 | 99.67 | 11,957,663 | 0.33 | 3,652,021,816 | 12,284,037 |
| 8 Re-election of Stacey Cartwright | 3,627,646,531 | 99.34 | 24,278,095 | 0.66 | 3,651,924,626 | 12,379,794 |
| 9 Re-election of Simon Dingemans | 3,611,625,566 | 98.90 | 40,202,459 | 1.10 | 3,651,828,025 | 12,477,828 |
| 10 Re-election of Lynn Elsenhans | 3,631,958,969 | 99.45 | 19,951,976 | 0.55 | 3,651,910,945 | 12,394,642 |
| 11 Re-election of Judy Lewent | 3,616,440,612 | 99.03 | 35,558,235 | 0.97 | 3,651,998,847 | 12,307,006 |
| 12 Re-election of Sir Deryck Maughan | 3,556,901,233 | 98.09 | 69,347,278 | 1.91 | 3,626,248,511 | 38,057,342 |
| 13 | 3,630,860,486 | 99.42 | 21,017,768 | 0.58 | 3,651,878,254 | 12,427,599 |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | | | | | | |
|----|-----------------------------------------------------------------------------------------------------------------------------|---------------|-------|-------------|-------|---------------|------------|
| | Re-election of Dr Daniel Podolsky | | | | | | |
| 14 | Re-election of Dr Moncef Slaoui | 3,631,852,758 | 99.45 | 20,032,722 | 0.55 | 3,651,885,480 | 12,420,374 |
| 15 | Re-election of Hans Wijers | 3,558,527,772 | 99.02 | 35,109,224 | 0.98 | 3,593,636,996 | 70,668,857 |
| 16 | Re-appointment of auditors | 3,497,872,211 | 97.19 | 101,054,446 | 2.81 | 3,598,926,657 | 65,379,196 |
| 17 | Remuneration of auditors | 3,534,642,170 | 98.21 | 64,277,018 | 1.79 | 3,598,919,188 | 65,386,223 |
| 18 | Authority for the company to make donations to political organisations and incur political expenditure | 3,577,744,022 | 98.02 | 72,255,599 | 1.98 | 3,649,999,621 | 14,306,463 |
| 19 | Authority to allot shares | 3,546,475,883 | 97.19 | 102,584,391 | 2.81 | 3,649,060,274 | 15,248,087 |
| 20 | Disapplication of pre-emption rights*** | 3,592,421,305 | 98.52 | 53,931,389 | 1.48 | 3,646,352,694 | 17,950,355 |
| 21 | Authority for the company to purchase its own shares*** | 3,646,045,423 | 99.84 | 5,930,054 | 0.16 | 3,651,975,477 | 12,330,810 |
| 22 | Exemption from statement of senior statutory auditor's name | 3,616,839,172 | 99.14 | 31,407,136 | 0.86 | 3,648,246,308 | 16,054,765 |
| 23 | Authorise reduced notice of a general meeting other than an AGM*** | 3,235,833,877 | 88.66 | 413,929,365 | 11.34 | 3,649,763,242 | 14,542,185 |
| 24 | Approval of GSK Share Value Plan | 3,528,728,822 | 96.72 | 119,600,001 | 3.28 | 3,648,328,823 | 15,980,071 |

Notes:

* Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

*** Indicates Special Resolutions requiring a 75% majority.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Sir Christopher Gent, Tom de Swaan and Jing Ulrich did not stand for re-election as Directors, and stepped down from the Board with effect from the conclusion of the AGM.

In accordance with section 430(2B) of the Companies Act 2006, GSK confirms that Sir Christopher Gent, Tom de Swaan and Jing Ulrich will receive payment of fees for service whilst a Director but no other remuneration payment or payment for loss of office will be made in connection with their departure.

The following table provides further relevant information:

| | GSK's Fifteenth AGM (2015) | GSK's Fourteenth AGM (2014) |
|-------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------|
| Issued share capital (excluding Treasury Shares) | 4,866,216,110 | 4,861,007,167 |
| Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) | 75.30% | 74.05% |
| Total shareholder population | 137,658 | 140,792 |
| Total number of proxies lodged | 8,686 | 8,333 |
| % of shareholders who lodged proxies | 6.31% | 5.92% |
| Number of shareholders, corporate representatives and proxies who attended the AGM | 403 | 429 |

V A Whyte
Company Secretary

7 May 2015

These results will shortly be available on the company's website at www.gsk.com.

GSK enquiries:

GSK enquiries:

| | | | |
|-----------------------------|-----------------|-------------------------|---------------------|
| UK Media enquiries: | David Mawdsley | +44 (0) 20 8047 5502 | (London) |
| | Simon Steel | +44 (0) 20 8047 5502 | (London) |
| | Sarah Spencer | +44 (0) 20 8047 5502 | (London) |
| US Media enquiries: | Stephen Rea | +1 215 751 4394 | (Philadelphia) |
| | Sarah Alspach | +1 202 715 1048 | (Washington, DC) |
| | Mary Anne Rhyne | +1 919 483 0492 | (North Carolina) |
| Analyst/Investor enquiries: | Ziba Shamsi | +44 (0) 20 8047 5543 | (London) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

| | | |
|-----------------|-------------------------|----------------|
| Tom Curry | + 1 215 751 5419 | (Philadelphia) |
| Gary Davies | +44 (0) 20 8047 5503 | (London) |
| James Dodwell | +44 (0) 20 8047 2406 | (London) |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 7, 2015

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc